Last update 25 Apr 2025

Brigatinib

Overview

Basic Info

Drug Type
Small molecule drug
Synonyms
Brigatinib (JAN/USAN), 布加替尼, 布吉他滨
+ [5]
Action
inhibitors, antagonists
Mechanism
ALK inhibitors(Anaplastic lymphoma kinase inhibitors), EGFR antagonists(Epidermal growth factor receptor erbB1 antagonists), FLT3 inhibitors(Tyrosine-protein kinase receptor FLT3 inhibitors)
Originator Organization
Inactive Organization-
Drug Highest PhaseApproved
First Approval Date
United States (28 Apr 2017),
RegulationAccelerated Approval (United States), Orphan Drug (United States), Breakthrough Therapy (United States)
Login to view timeline

Structure/Sequence

Molecular FormulaC29H39ClN7O2P
InChIKeyAILRADAXUVEEIR-UHFFFAOYSA-N
CAS Registry1197953-54-0

External Link

KEGGWikiATCDrug Bank
D10866Brigatinib

R&D Status

Approved
10 top approved records.
Login
to view more data
IndicationCountry/LocationOrganizationDate
ALK positive Non-Small Cell Lung Cancer
United States
28 Apr 2017
Developing
10 top R&D records.
Login
to view more data
IndicationHighest PhaseCountry/LocationOrganizationDate
ALK positive Lung CancerPhase 3
United States
26 May 2016
ALK positive Lung CancerPhase 3
Australia
26 May 2016
ALK positive Lung CancerPhase 3
Austria
26 May 2016
ALK positive Lung CancerPhase 3
Canada
26 May 2016
ALK positive Lung CancerPhase 3
Denmark
26 May 2016
ALK positive Lung CancerPhase 3
France
26 May 2016
ALK positive Lung CancerPhase 3
Germany
26 May 2016
ALK positive Lung CancerPhase 3
Hong Kong
26 May 2016
ALK positive Lung CancerPhase 3
Italy
26 May 2016
ALK positive Lung CancerPhase 3
Luxembourg
26 May 2016
Login to view more data

Clinical Result

Indication
Phase
Evaluation
View All Results
Study
Phase
PopulationAnalyzed EnrollmentGroupResultsEvaluationPublication Date
Not Applicable
Nervous System Neoplasms
anaplastic lymphoma kinase fusion
1,016
rgeurfhjjo(utaklpyivk) = fpvrtfncyf dbruemmcvq (kohtwlfdse, 48.03 - 65.67)
Positive
07 Apr 2025
Not Applicable
331
sadflydbbj(trwoiirmyi) = The most common events on the Patient-Reported Outcomes version of the Common Terminology Criteria for Adverse Events (PRO CTCAE) during 1L BRG treatment were gastrointestinal toxicities (64%, 34/53), including nausea (77%, 26/34), vomiting (56%, 19/34) and diarrhea (56%, 19/34) mpfsjxagmk (bhjuxqtreh )
-
26 Mar 2025
Phase 3
248
(Brigatinib)
ekfceoqski(yshyqvglzb) = pyvoirdqce qhqmnhtcsr (lsazowlmnl, dmcfyxcjsl - mkmcwgfule)
-
19 Feb 2025
(Alectinib)
ekfceoqski(yshyqvglzb) = zkcyijlntb qhqmnhtcsr (lsazowlmnl, bfjooswnee - ftwcfofufh)
Phase 3
136
kzkmbzytwg(pbrbjgjtlw) = qhhpnkoqlv ckdlcwucpy (zhhslwhcny, 21.1 - 44.1)
Positive
14 Sep 2024
Placebo
kzkmbzytwg(pbrbjgjtlw) = eixlgmqxog ckdlcwucpy (zhhslwhcny, 23.9 - NR)
ESMO2024
ManualManual
Not Applicable
ALK positive Non-Small Cell Lung Cancer
First line
ALK Rearrangement
242
Alectinib
entzvowolf(pcfrcdfvxw) = pmagyunfsk ljhxjoehjt (fnqhrremyv )
Positive
14 Sep 2024
entzvowolf(pcfrcdfvxw) = kxmsnfmqdf ljhxjoehjt (fnqhrremyv )
Phase 2
Non-small cell lung cancer stage IIIB | metastatic non-small cell lung cancer
First line
ALK fusion variants | tumor mutational burden (TMB) | ctDNA levels
30
rybcuhgxsw(xtkxojbvqh) = lvbjkiaraa yxwbgciznc (mydarhmvut, 75.1 - 98.4)
-
14 Sep 2024
Phase 3
48
ALK TKI brigatinib
(post-1L brigatinib)
jdkowhkftx(eyfeuvvvwz) = veopjufbkv xnaunxaplb (azhcqasgek )
Positive
08 Sep 2024
Lorlatinbrigatinib
jdkowhkftx(eyfeuvvvwz) = mvxqxvcbxa xnaunxaplb (azhcqasgek )
Phase 2
40
Brigatinib 180 mg
ktgwbwvncp(eehyriqydf) = gbavyccrek rwvmmzyrfd (kpjsjxkgou, 3 - 24)
Positive
27 Jun 2024
Phase 3
30
Lorlatinib
mvqynjqget(akiisnnjpd) = zbeltqvpqt ifdbhjxjjr (ilrgthevja )
Positive
22 Mar 2024
Login to view more data

Translational Medicine

Boost your research with our translational medicine data.
Boost your research with our translational medicine data.

Deal

Boost your decision using our deal data.
Boost your decision using our deal data.

Core Patent

Boost your research with our Core Patent data.
Boost your research with our Core Patent data.

Clinical Trial

Identify the latest clinical trials across global registries.
Identify the latest clinical trials across global registries.

Approval

Accelerate your research with the latest regulatory approval information.
Accelerate your research with the latest regulatory approval information.

Regulation

Understand key drug designations in just a few clicks with Synapse.
Understand key drug designations in just a few clicks with Synapse.
Chat with Hiro
Get started for free today!
Accelerate Strategic R&D decision making with Synapse, PatSnap’s AI-powered Connected Innovation Intelligence Platform Built for Life Sciences Professionals.
Start your data trial now!
Synapse data is also accessible to external entities via APIs or data packages. Empower better decisions with the latest in pharmaceutical intelligence.
Bio
Bio Sequences Search & Analysis
Sign up for free
Chemical
Chemical Structures Search & Analysis
Sign up for free